Core Insights - Phreesia, Inc. is set to release its quarterly earnings on December 8, 2025, with analysts estimating an EPS of $0.24 and revenue of approximately $120 million [1][5] - The projected revenue of $120.13 million represents a 12.5% increase compared to the same quarter last year, indicating positive growth for the company [2][5] - The company's price-to-sales ratio is 2.72, and the enterprise value to sales ratio is 2.51, suggesting efficient capital use [3] - Phreesia has a low debt-to-equity ratio of 0.016, indicating minimal reliance on debt financing, and a current ratio of 2.12, reflecting a strong ability to cover short-term liabilities [3] Financial Metrics - Analysts estimate an EPS of $0.24 for the upcoming earnings report [5] - Projected quarterly revenue is $120.13 million, marking a 12.5% year-over-year increase [2][5] - The price-to-sales ratio of 2.72 indicates investors are willing to pay $2.72 for every dollar of sales [3] - The enterprise value to sales ratio of 2.51 suggests efficient capital utilization [3] Market Expectations - The upcoming earnings report and management discussion will be critical for determining future earnings expectations and stock price movements [4] - Investors are closely monitoring whether Phreesia will exceed earnings expectations, as a positive earnings report could lead to a stock price increase [4]

Company Overview - Phreesia, Inc. is a healthcare technology company focused on patient intake and engagement, aiming to enhance the patient experience and healthcare outcomes [1] Financial Performance - Phreesia's Return on Invested Capital (ROIC) is 0.52%, which is significantly lower than its Weighted Average Cost of Capital (WACC) of 7.01%, indicating inefficiency in capital utilization [2][6] - The ROIC to WACC ratio for Phreesia is 0.074, further highlighting its challenges in generating returns above its cost of capital [2][6] Peer Comparison - Health Catalyst has a negative ROIC of -16.99% against a WACC of 6.57%, resulting in a ROIC to WACC ratio of -2.59, indicating worse performance than Phreesia [3] - Veracyte has a ROIC of 0.99% and a WACC of 13.50%, with a ROIC to WACC ratio of 0.073, suggesting it also struggles to generate sufficient returns, but is noted for having the highest growth potential among peers [4][6] - Accolade, Castle Biosciences, and Personalis all report negative ROICs of -31.79%, -4.28%, and -30.51% respectively, with their WACCs at 10.94%, 8.83%, and 11.72%, indicating significant challenges in generating returns above their cost of capital [5]